open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-20
Get Citation

Qualification for TKI-EGFR inhibitors treatment in a patient diagnosed with adenocarcinoma of the lung with activating mutation in EGFR gene

Sławomir Mańdziuk, Magdalena Wójcik-Superczyńska

open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-20

Abstract

Lung cancer is the leading cause of cancer death in Poland and other development counties both in females and males population. Histopathological diagnosis and immunochemistry examination of adenocarcinoma should not finish a diagnostic process, because in patients with adenocarcinoma, the detection of EGFR activating mutation become a diagnostic standard. Currently the sensitive methods based on real time PCR techniques for EGFR mutation analysis are used in laboratory practice. Evaluation of EGFR mutation determines the possibility of patients` qualification to molecularly targeted therapies. Erlotinib, the reversible tyrosine kinase inhibitor (TKI-EGFR) is effective agent both in first line of treatment and maintenance therapy in non-small cell lung cancer (NSCLC) patients, mainly with activating EGFR mutations in tumor cells.

Abstract

Lung cancer is the leading cause of cancer death in Poland and other development counties both in females and males population. Histopathological diagnosis and immunochemistry examination of adenocarcinoma should not finish a diagnostic process, because in patients with adenocarcinoma, the detection of EGFR activating mutation become a diagnostic standard. Currently the sensitive methods based on real time PCR techniques for EGFR mutation analysis are used in laboratory practice. Evaluation of EGFR mutation determines the possibility of patients` qualification to molecularly targeted therapies. Erlotinib, the reversible tyrosine kinase inhibitor (TKI-EGFR) is effective agent both in first line of treatment and maintenance therapy in non-small cell lung cancer (NSCLC) patients, mainly with activating EGFR mutations in tumor cells.

Get Citation

Keywords

EGFR (epidermal growth factor receptor), erlotinib, lung cancer, targeted therapy

About this article
Title

Qualification for TKI-EGFR inhibitors treatment in a patient diagnosed with adenocarcinoma of the lung with activating mutation in EGFR gene

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. G (2014)

Pages

14-17

Published online

2015-03-20

Keywords

EGFR (epidermal growth factor receptor)
erlotinib
lung cancer
targeted therapy

Authors

Sławomir Mańdziuk
Magdalena Wójcik-Superczyńska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl